Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CYP11B1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for CYP11B1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Clazakizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Clazakizumab is a Monoclonal antibody targeting IL-6, at Phase 2/3. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.
Latest Hotspot
8 min read
Roflumilast Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Roflumilast is a Small molecule drug targeting PDE4, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Ibrexafungerp Citrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ibrexafungerp Citrate is a Small molecule drug targeting 1,3-beta-glucan synthase, at Approved. This 2026 report reviews clinical evidence, IP, deals.
8 min read
CYP11A1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for CYP11A1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Mavacamten Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Mavacamten is a Small molecule drug targeting Cardiac myosin, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Sonelokimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Sonelokimab is a Nanobody, Trispecific antibody targeting IL-17A x IL-17F x albumin, at Phase 3. This 2026 report reviews clinical evidence, IP, deals.
Latest Hotspot
8 min read
Acoramidis Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Acoramidis is a Small molecule drug targeting TTR, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
COMT 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for COMT, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Ivonescimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ivonescimab is a Bispecific antibody targeting PD-1 x VEGF-A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
CHD8 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for CHD8, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHD7 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for CHD7, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.